Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

amsacrine

An aminoacridine derivative with potential antineoplastic activity. Although its mechanism of action is incompletely defined, amsacrine may intercalate into DNA and inhibit topoisomerase II, resulting in DNA double-strand breaks, arrest of the S/G2 phase of the cell cycle, and cell death. This agent's cytotoxicity is maximal during the S phase of the cell cycle when topoisomerase levels are greatest. In addition, amsacrine may induce transcription of tumor promoter p53 protein and block p53 ubiquitination and proteasomal degradation, resulting in p53-dependent tumor cell apoptosis.
Synonym:acridinyl anisidide
Cain's acridine
US brand name:Amsa P-D
Foreign brand name:Amekrin
Amsidine
Amsidyl
Lamasine
Abbreviation:AMSA
m-AMSA
Code name:CI 880
CI-880
CI880
SN-11841
SN-21429
SN11841
Chemical structure:4'-(9-acridinylamino)methane-sulfon-m-anisidide
N-[4-(9-acridinylamino)-3-methoxyphenyl]methanesulfonamide
Search NCI's Drug Dictionary